{"id":"CHEMBL102358","canonicalSmiles":"O=C(/C=C/c1ccccc1)NCCO","inchiKey":"OSCTXCOERRNGLW-VOTSOKGWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IDROCILAMIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Idrocilamide","NSC-44979","NSC-58207","NSC-63229","Srilane"],"crossReferences":{"PubChem":["144205698","170466602","26757929"],"drugbank":["DB13297"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1081615","canonicalSmiles":"COc1[nH]c(=O)c(C(=O)[C@@H](C)C[C@H](C)[C@@H](Cl)CCl)c(O)c1OC","inchiKey":"OVULNOOPECCZRG-CIUDSAMLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ATPENIN A5","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Atpenin A5"],"crossReferences":{"drugbank":["DB04631"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1084617","canonicalSmiles":"COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1","inchiKey":"ZEOQUKRCASTCFR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEMANOGREL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["APD-791","APD791","Apd791","Temanogrel"],"childChemblIds":["CHEMBL2105696"],"linkedTargets":{"rows":["ENSG00000102468"],"count":1},"linkedDiseases":{"rows":["EFO_0005672"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1108","canonicalSmiles":"O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1","inchiKey":"RMEDXOLNCUSCGS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DROPERIDOL","yearOfFirstApproval":1970,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dridol","Droleptan","Droperidol","Inapsine"],"synonyms":["Droperidol","MCN-JR-4749","NSC-169874","R-4749"],"crossReferences":{"DailyMed":["droperidol"],"PubChem":["11112409","124882342","144204012","170464722","26719691","26748461","56463295","855921"],"Wikipedia":["Droperidol"],"drugbank":["DB00450"],"chEBI":["4717"]},"linkedTargets":{"rows":["ENSG00000069696","ENSG00000149295","ENSG00000102468","ENSG00000151577"],"count":4},"linkedDiseases":{"rows":["EFO_1000864","HP_0002017","EFO_0004888","EFO_0005407","HP_0002013","EFO_0003843"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1164729","canonicalSmiles":"Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O","inchiKey":"BQSJTQLCZDPROO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FEBUXOSTAT","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adenuric","Uloric"],"synonyms":["Febuxostat","NSC-758874","TMX-67"],"crossReferences":{"DailyMed":["febuxostat"],"PubChem":["124893781","144206555","170465220"],"Wikipedia":["Febuxostat"],"drugbank":["DB04854"]},"linkedTargets":{"rows":["ENSG00000158125"],"count":1},"linkedDiseases":{"rows":["EFO_0003086","EFO_0009104","EFO_0003095","EFO_0004253","EFO_0004274","MONDO_0005147","EFO_0001645","Orphanet_976","EFO_0000319","EFO_1001479","EFO_0000537","EFO_0003913"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for hyperuricemia and gout and has 7 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200359","canonicalSmiles":"COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1","inchiKey":"GPTONYMQFTZPKC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFAMETER","yearOfFirstApproval":1966,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Germany"],"year":1988},"tradeNames":["Bayrena","Sulfametin","Sulfametoxydiazine","Sulla","Sulphamethoxydiazine","Ultrax"],"synonyms":["AHR-857","BAY-5400","NSC-683528","NSC-757874","SH-613","Sulfameter","Sulfamethoxydiazine","Sulfamethoxypyrimidine","Sulfametin","Sulfametoxydiazine","Sulphamethoxydiazine","Ultrax"],"crossReferences":{"PubChem":["11112435","144204029","170465428","26748523","855817"],"Wikipedia":["Sulfametoxydiazine"],"drugbank":["DB06821"],"chEBI":["53727"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1966 and is indicated for bacterial disease. It was withdrawn in Germany  in 1988."}
{"id":"CHEMBL1200377","canonicalSmiles":"CC(N)Cc1ccccc1.NC(CC(=O)O)C(=O)O","inchiKey":"DYOBNLAYPQSBLB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMPHETAMINE ASPARTATE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL405","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Amfetamine aspartate","Amphetamine aspartate"],"crossReferences":{"DailyMed":["amphetamine%20aspartate"]},"linkedTargets":{"rows":["ENSG00000103546","ENSG00000142319"],"count":2},"linkedDiseases":{"rows":["EFO_0003888"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996 and has 1 investigational indication."}
{"id":"CHEMBL1200425","canonicalSmiles":"C#CCN(C)Cc1ccccc1.Cl","inchiKey":"BCXCABRDBBWWGY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PARGYLINE HYDROCHLORIDE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL673","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Eutonyl"],"synonyms":["A-19120","MO-911","NSC-43798","Pargyline hcl","Pargyline hydrochloride"],"crossReferences":{"PubChem":["144203792","144212995","170465066","50106924","56422872","855526"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1200781","canonicalSmiles":"Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21","inchiKey":"WIHMBLDNRMIGDW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CITALOPRAM HYDROBROMIDE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL549","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Celexa","Cipramil","Citalopram hydrobromide","Paxoran"],"synonyms":["Citalopram (as hydrobromide)","Citalopram hbr","Citalopram hydrobromide","LU 10-171-B","LU-10-171-B","NSC-758684"],"crossReferences":{"DailyMed":["citalopram%20hydrobromide"],"PubChem":["26719710","29215151","46500388","50106010","50106011"]},"linkedTargets":{"rows":["ENSG00000108576"],"count":1},"linkedDiseases":{"rows":["MONDO_0002050","EFO_0004262","MONDO_0002009","EFO_0003758","EFO_0003761","HP_0031217"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for major depressive disorder and unipolar depression and has 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201061","canonicalSmiles":"CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.Cl","inchiKey":"OWNWYCOLFIFTLK-YDALLXLXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVALBUTEROL HYDROCHLORIDE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1002","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Levalbuterol hydrochloride","Xopenex"],"synonyms":["Albuterol (r)-form hydrochloride","Albuterol hydrochloride, r-","Levalbuterol hcl","Levalbuterol hydrochloride","Levosalbutamol hydrochloride","NSC-759255"],"crossReferences":{"DailyMed":["levalbuterol%20hydrochloride"]},"linkedTargets":{"rows":["ENSG00000169252"],"count":1},"linkedDiseases":{"rows":["MONDO_0004979"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999 and is indicated for asthma."}
{"id":"CHEMBL1201505","drugType":"Unknown","blackBoxWarning":false,"name":"FIBRINOLYSIN, HUMAN","yearOfFirstApproval":1964,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Actase"],"synonyms":["Fibrinolysin","Fibrinolysin (human)","Fibrinolysin human","Fibrinolysin, human","Plasmin","Plasmin (bos taurus)","Plasmin (bovine)","Plasmin (human)","Plasmin bovine","Thrombolysin."],"crossReferences":{"Wikipedia":["Fibrinolysin"]},"linkedTargets":{"rows":["ENSG00000171560","ENSG00000171564","ENSG00000171557"],"count":3},"linkedDiseases":{"rows":["HP_0002140","HP_0004419","MONDO_0020673"],"count":3},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for recurrent thrombophlebitis and has 1 investigational indication."}
{"id":"CHEMBL1201653","drugType":"Protein","blackBoxWarning":false,"name":"INSULIN ZINC SUSP PURIFIED PORK","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lente","Lente iletin ii (pork)"],"synonyms":["Insulin zinc susp purified pork"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1979."}
{"id":"CHEMBL1201799","canonicalSmiles":"C=CCN.ClCC1CO1.O=C(O)O","inchiKey":"PADGNZFOVSZIKZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SEVELAMER CARBONATE","yearOfFirstApproval":2007,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201798","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Renvela"],"synonyms":["GT-335-012","GT335-012","Sevelamer carbonate"],"crossReferences":{"DailyMed":["sevelamer%20carbonate"],"DrugCentral":["4331"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic kidney disease and has 4 investigational indications."}
{"id":"CHEMBL121291","canonicalSmiles":"NS(=O)(=O)c1ccc(N2CCCC2=O)c([N+](=O)[O-])c1","inchiKey":"FPCPYSKJIRSWIG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL121291","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["24786794"],"drugbank":["DB04394"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1213492","canonicalSmiles":"CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(=O)NO)cc3)ccc2c1","inchiKey":"YALNUENQHAQXEA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GIVINOSTAT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Givinostat"],"crossReferences":{"drugbank":["DB12645"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL1236872","canonicalSmiles":"Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O","inchiKey":"OIRDTQYFTABQOQ-GAWUUDPSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1236872","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["50105851"],"drugbank":["DB03528"],"chEBI":["46515"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1368","canonicalSmiles":"O=P([O-])(O)O.[Na+]","inchiKey":"AJPJDKMHJJGVTQ-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM PHOSPHATE, MONOBASIC","yearOfFirstApproval":1983,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ionosol B","Ionosol Mb","Ionosol T"],"synonyms":["E-339(I)","E339","INS NO.339(I)","INS-339(I)","Monobasic sodium phosphate","Monosodium phosphate","Monosodium phosphate, anhydrous","Sodium Phosphate, Monobasic","Sodium acid phosphate","Sodium biphosphate","Sodium biphosphate, anhydrous","Sodium dihydrogen phosphate","Sodium orthophosphate monobasic","Sodium phosphate monobasic","Sodium phosphate monobasic (anhydrous)","Sodium phosphate, monobasic","Sodium phosphate, monobasic anhydrous","Sodium phosphate, monobasic, anhydrous","Sodium phosphate, monobasic, monohydrate","Sodium phosphate,monobasic","Sodium primary phosphate"],"crossReferences":{"DailyMed":["sodium%20phosphate,%20monobasic,%20monohydrate"],"DrugCentral":["4271","4295"],"Wikipedia":["Monosodium_phosphate"],"drugbank":["DB09449"],"chEBI":["37585"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and is indicated for constipation disorder and urinary tract infection."}
{"id":"CHEMBL13766","canonicalSmiles":"COc1ccccc1O","inchiKey":"LHGVFZTZFXWLCP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GUAIACOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(mu)-methoxyphenol","Creodon","FEMA NO. 2532","Guaiacol","Guaiastil","NSC-3815","O-guaiacol","O-hydroxyanisole","Pyroguaiac acid"],"crossReferences":{"PubChem":["144204582","144208334","144210188","144213965","17388828","17389094","17389539","49825822"],"Wikipedia":["Guaiacol"],"drugbank":["DB11359"],"chEBI":["28591"]},"childChemblIds":["CHEMBL224145"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL1413","canonicalSmiles":"Cc1cc(C2CCCCC2)n(O)c(=O)c1","inchiKey":"SCKYRAXSEDYPSA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CICLOPIROX","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ciclopirox","Loprox","Penlac"],"synonyms":["Ciclopirox","Cyclopirox","HOE 296B","HOE-296B"],"crossReferences":{"DailyMed":["ciclopirox"],"Wikipedia":["Ciclopirox"],"drugbank":["DB01188"],"chEBI":["453011"]},"childChemblIds":["CHEMBL242580"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 4 approved and 2 investigational indications."}
{"id":"CHEMBL14192","canonicalSmiles":"c1ccc(Cn2ccnc2)cc1","inchiKey":"KKKDZZRICRFGSD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BENZYLIMIDAZOLE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Benzylimidazole"],"crossReferences":{"PubChem":["855733"],"drugbank":["DB04581"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL142130","canonicalSmiles":"CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C","inchiKey":"DUSHUSLJJMDGTE-ZJPMUUANSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CYPROTERONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cyproterone","NSC-758636"],"crossReferences":{"PubChem":["144204968"],"Wikipedia":["Cyproterone_acetate"],"chEBI":["50742"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1475","canonicalSmiles":"Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1","inchiKey":"FMHHVULEAZTJMA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIOXSALEN","yearOfFirstApproval":1964,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Trisoralen"],"synonyms":["4,5',8-trimethylpsoralen","NSC-71047","Tmp (psoralen)","Trioxsalen","Trioxysalen"],"crossReferences":{"PubChem":["11112550","114185","144204092","170465339","174006210","26748294","49647255"],"Wikipedia":["Trioxsalen"],"drugbank":["DB04571"],"chEBI":["28329"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1964 and is indicated for psoriasis."}
{"id":"CHEMBL158766","canonicalSmiles":"Cc1ccc(O)c(O)c1","inchiKey":"ZBCATMYQYDCTIZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL158766","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144207830"],"drugbank":["DB04120"],"chEBI":["17254"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1589","canonicalSmiles":"CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1","inchiKey":"VGZSUPCWNCWDAN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACETOHEXAMIDE","yearOfFirstApproval":1964,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Acetohexamide","Dimelor","Dymelor"],"synonyms":["33006","Acetohexamide","NSC-759128"],"crossReferences":{"PubChem":["11110689","11112460","144203618","144209220","144213052","170465411","17390067","50105548","56463352"],"Wikipedia":["Acetohexamide"],"drugbank":["DB00414"],"chEBI":["28052"]},"linkedTargets":{"rows":["ENSG00000187486","ENSG00000006071"],"count":2},"linkedDiseases":{"rows":["MONDO_0005129","EFO_0000400"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for diabetes mellitus and has 1 investigational indication."}
{"id":"CHEMBL1623992","canonicalSmiles":"CCN1CCCC(OC(=O)C(c2ccccc2)c2ccccc2)C1","inchiKey":"KTHVBAZBLKXIHZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIPERIDOLATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["1087-A.N.","JB-305","Piperidolate"],"crossReferences":{"drugbank":["DB13351"]},"childChemblIds":["CHEMBL1511957"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for gastrointestinal disease."}
{"id":"CHEMBL1628698","canonicalSmiles":"COc1ccc(-c2ccc(OCc3cc(C(=O)NS(=O)(=O)c4ccccc4C)oc3C)cc2)nc1","inchiKey":"IXDVRRPNWPOPGV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BGC-20-1531 FREE BASE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BGC-201531"],"childChemblIds":["CHEMBL3260771"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1630563","canonicalSmiles":"O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(-c3ccc(OC(F)(F)F)cc3)nc1)C2","inchiKey":"ZXSGSFMORAILEY-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TBA-354","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TBA 354","Tba-354"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL165372","canonicalSmiles":"O=[N+]([O-])c1ccc2[nH]ncc2c1","inchiKey":"WSGURAYTCUVDQL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL165372","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144210123","24811413"],"drugbank":["DB04534"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1697831","canonicalSmiles":"CN(C)C(=O)CCCOC(=O)C(C)(C)Oc1ccc(Cl)cc1","inchiKey":"CXQGFLBVUNUQIA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLOFIBRIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Clofibride"],"crossReferences":{"drugbank":["DB13849"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1697851","canonicalSmiles":"CC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1","inchiKey":"AIUHRQHVWSUTGJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"THIOPROPAZATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Thiopropazate"],"crossReferences":{"drugbank":["DB13557"],"chEBI":["59119"]},"childChemblIds":["CHEMBL3989786"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for psychosis."}
{"id":"CHEMBL1711","canonicalSmiles":"CC(C)NCC(O)c1ccc(O)c(O)c1.Cl","inchiKey":"IROWCYIEJAOFOW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ISOPROTERENOL HYDROCHLORIDE","yearOfFirstApproval":1956,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL434","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aerolone","Imuprel","Isoprenaline","Isoproterenol hydrochloride","Isuprel","Norisodrine","Norisodrine aerotrol","Oriconazole","Vapo-iso"],"synonyms":["Aerotrol","Dl-isoprenaline hydrochloride","Euspiran","Isomenyl","Isoprenaline hydrochloride","Isoprenaline hydrochloride, dl-","Isopropylarterenol hydrochloride","Isoproterenol HCl","Isoproterenol hcl","Isoproterenol hydrochloride","Isovon","L-isoprenaline hydrochloride","Medihaler-Iso","Mistarel","NSC-37745","NSC-89747","Suscardia"],"crossReferences":{"DailyMed":["isoproterenol%20hydrochloride"],"PubChem":["144208470","144210628","17388957","26747558","26747559","26752241","50085961","50106483","50106527","50106528","56320927","56320928"]},"linkedTargets":{"rows":["ENSG00000169252","ENSG00000043591","ENSG00000188778"],"count":3},"linkedDiseases":{"rows":["EFO_0000373"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and is indicated for congestive heart failure."}
{"id":"CHEMBL1717","canonicalSmiles":"Cl.Clc1ccccc1CN1CCc2sccc2C1","inchiKey":"MTKNGOHFNXIVOS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TICLOPIDINE HYDROCHLORIDE","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL833","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ticlid","Ticlopidine hydrochloride","Tiklid"],"synonyms":["4-C-32","53-32C","Ipaton","NSC-759165","Ticlopidine hcl","Ticlopidine hydrochloride"],"crossReferences":{"DailyMed":["ticlopidine%20hydrochloride"],"PubChem":["865815"],"chEBI":["9589"]},"linkedTargets":{"rows":["ENSG00000169313"],"count":1},"linkedDiseases":{"rows":["MONDO_0000831","EFO_0000712"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for thrombotic disease and stroke. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1723","canonicalSmiles":"COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl","inchiKey":"YTNKWDJILNVLGX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALFUZOSIN HYDROCHLORIDE","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL709","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alfutral sr","Alfuzosin hydrochloride","Benestan","Benestan ret","Besavar xl","Fuzatal xl","Kelanu xl","Urion s","Uroxatral","Vasran xl","Xatral","Xatral sr","Zufal xl"],"synonyms":["Alfuzosin hcl","Alfuzosin hydrochloride","SL 77 499-10","SL-77-499-10","SL-77499-10"],"crossReferences":{"DailyMed":["alfuzosin%20hydrochloride"],"PubChem":["144204252","170465022"],"chEBI":["32286"]},"linkedTargets":{"rows":["ENSG00000171873","ENSG00000170214","ENSG00000120907"],"count":3},"linkedDiseases":{"rows":["EFO_0004253","EFO_1001228","EFO_0000284"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for benign prostatic hyperplasia and has 2 investigational indications."}
{"id":"CHEMBL1733","canonicalSmiles":"C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O","inchiKey":"FLSLEGPOVLMJMN-YSSFQJQWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"QUINAPRILAT","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CI-928","NSC-759825","Quinapril diacid","Quinapril related compound b","Quinaprilat"],"crossReferences":{"Wikipedia":["Quinaprilat"],"drugbank":["DB14217"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL174","canonicalSmiles":"CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O","inchiKey":"AVKUERGKIZMTKX-NJBDSQKTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMPICILLIN","yearOfFirstApproval":1965,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Amcill","Amfipen","Ampicillin trihydrate","Ampilar","Britcin","Omnipen","Omnipen (ampicillin)","Penbritin","Pfizerpen-a","Polycillin","Principen","Principen '125'","Principen '250'","Principen '500'","Totacillin","Vidopen"],"synonyms":["AY-6108","Alpha-Aminobenzylpenicillin","Amcill","Aminobenzylpenicillin","Aminobenzylpenicillin trihydrate","Ampicillin","Ampicillin (anhydrous)","Ampicillin anhydrous","Ampicillin hydrate","Ampicillin, anhydrous","Ampicillin/ampicillin trihydrate","Ampicillinum","Anhydrous ampicillin","BRL-1341","NSC-528986","Omnipen-N","P-50","Penbritin","Penbritin-S","Pfizerpen-A","Poly-cillin","Polycillin","Polycillin-N","Polycillin-Prb","Principen","Probampacin","Redicilin","Semicillin","Tokiocillin","Totacillin","Totacillin-N","Ultrabion","WY 5103"],"crossReferences":{"DailyMed":["ampicillin%20sodium"],"PubChem":["144206600","144211733","170464831","29215015","56422904","855874"],"Wikipedia":["Ampicillin"],"drugbank":["DB00415"],"chEBI":["28971"]},"childChemblIds":["CHEMBL453388","CHEMBL1200758","CHEMBL1078033"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 8 approved and 8 investigational indications."}
{"id":"CHEMBL1742423","canonicalSmiles":"CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21","inchiKey":"ACCMWZWAEFYUGZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BILASTINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ilaxten"],"synonyms":["Bilastine"],"crossReferences":{"PubChem":["170466329"],"drugbank":["DB11591"]},"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0005854","EFO_0005531","MONDO_0005271","EFO_0007141","EFO_1001417","EFO_0003956","EFO_1001881"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for allergic disease and has 4 investigational indications."}
{"id":"CHEMBL1743063","drugType":"Antibody","blackBoxWarning":false,"name":"RILOTUMUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG 102","AMG-102","Rilotumumab"],"linkedTargets":{"rows":["ENSG00000019991"],"count":1},"linkedDiseases":{"rows":["MONDO_0001056","EFO_0000588","MONDO_0100342","EFO_0000681","EFO_1001465","EFO_0000702","EFO_0000708","MONDO_0008315"],"count":8},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL180101","canonicalSmiles":"CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1","inchiKey":"CBQGYUDMJHNJBX-OALUTQOASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ESREBOXETINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(s,s)-reboxetine","Esreboxetine","REBOXETINE","S,s-reboxetine"],"crossReferences":{"PubChem":["11114256"],"drugbank":["DB12395"]},"childChemblIds":["CHEMBL2103809"],"linkedTargets":{"rows":["ENSG00000103546"],"count":1},"linkedDiseases":{"rows":["EFO_1000783","EFO_0005687","EFO_0003843"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1822792","canonicalSmiles":"CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1","inchiKey":"JGEBLDKNWBUGRZ-HXUWFJFHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-2461","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK-2461","Mk-2461"],"linkedTargets":{"rows":["ENSG00000105976"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000311"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1852688","canonicalSmiles":"CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1","inchiKey":"QADPYRIHXKWUSV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INFIGRATINIB","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["BGJ-398","BGJ398","Bgj-398","Infigratinib","MVP-BGJ398","NVP-BGJ398"],"crossReferences":{"drugbank":["DB11886"],"chEBI":["63451"]},"childChemblIds":["CHEMBL1834657"],"linkedTargets":{"rows":["ENSG00000066468","ENSG00000068078","ENSG00000077782","ENSG00000160867"],"count":4},"linkedDiseases":{"rows":["EFO_0000616","Orphanet_15","EFO_1002027","EFO_0000756","Orphanet_44890","MONDO_0007254","MONDO_0044704","EFO_0005221","MONDO_0020654","EFO_0000311","MONDO_0001187","EFO_0001061","EFO_0001668","EFO_0006544","EFO_0000519"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for cholangiocarcinoma and has 13 investigational indications."}
{"id":"CHEMBL1983268","canonicalSmiles":"CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1","inchiKey":"HAYYBYPASCDWEQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENTRECTINIB","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Rozlytrek"],"synonyms":["Entrectinib","NMS-E628","RXDX-101","Rxdx-101"],"crossReferences":{"DailyMed":["entrectinib"],"PubChem":["103905026"],"drugbank":["DB11986"]},"linkedTargets":{"rows":["ENSG00000140538","ENSG00000171094","ENSG00000148053","ENSG00000047936","ENSG00000198400"],"count":5},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000553","EFO_1000616","EFO_0000389","EFO_0000326","MONDO_0024880","EFO_0003060","EFO_0000311"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 3 investigational indications."}
{"id":"CHEMBL2028019","canonicalSmiles":"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1","inchiKey":"KPWSJANDNDDRMB-QAQDUYKDSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CARIPRAZINE","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Reagila"],"synonyms":["Cariprazine","Fri-7000188","GED-129","MP-214","RGH-188"],"crossReferences":{"DailyMed":["cariprazine%20hydrochloride"],"drugbank":["DB06016"]},"childChemblIds":["CHEMBL2024517"],"linkedTargets":{"rows":["ENSG00000149295","ENSG00000151577"],"count":2},"linkedDiseases":{"rows":["EFO_0003888","MONDO_0005090","EFO_0003756","EFO_1001892","EFO_0000289","MONDO_0002050","MONDO_0002009","EFO_0009963","EFO_0005407","EFO_0010445"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2041933","canonicalSmiles":"NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1","inchiKey":"IAYGCINLNONXHY-LBPRGKRZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-7762","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-7762","AZD7762","Azd 7762","Azd-7762"],"crossReferences":{"PubChem":["124950686"],"drugbank":["DB12242"]},"linkedTargets":{"rows":["ENSG00000149554"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000311"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2043437","canonicalSmiles":"CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1","inchiKey":"SFNSLLSYNZWZQG-VQIMIIECSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"GLASDEGIB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Glasdegib","PF-04449913","PF-4449913"],"crossReferences":{"DailyMed":["glasdegib%20maleate"],"drugbank":["DB11978"]},"childChemblIds":["CHEMBL4297534","CHEMBL2043440"],"linkedTargets":{"rows":["ENSG00000128602"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","MONDO_0013730","EFO_0000616","MONDO_0019457","EFO_0000222","EFO_1001968","EFO_0000519","EFO_1001934","EFO_0000311"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL204997","canonicalSmiles":"N=C(N)c1ccc2[nH]c(-c3n[nH]c(-c4ccccc4)c3O)nc2c1","inchiKey":"CKSIVONWCYACAP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL204997","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07207"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL206253","canonicalSmiles":"Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1","inchiKey":"WAXQNWCZJDTGBU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NETUPITANT","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Netupitant","RO 67-3189/000","RO-67-3189","RO-673189000"],"crossReferences":{"DailyMed":["netupitant"],"drugbank":["DB09048"],"chEBI":["85155"]},"linkedTargets":{"rows":["ENSG00000115353"],"count":1},"linkedDiseases":{"rows":["EFO_0006911","EFO_0000311"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for chemotherapy-induced nausea and vomiting and has 1 investigational indication."}
{"id":"CHEMBL2074922","canonicalSmiles":"CC1=C(C(=O)OCCN(Cc2ccccc2)c2ccccc2)C(c2cccc([N+](=O)[O-])c2)C(P2(=O)OCC(C)(C)CO2)=C(C)N1","inchiKey":"NSVFSAJIGAJDMR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EFONIDIPINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Efonidipine","Efonidipine hydrochloride"],"crossReferences":{"PubChem":["144206968"],"drugbank":["DB09235"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2097081","drugType":"Small molecule","blackBoxWarning":true,"name":"NITROPRUSSIDE","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Nitroprusside"],"crossReferences":{"DailyMed":["sodium%20nitroprusside"],"DrugCentral":["4631"],"PubChem":["29217813"],"chEBI":["7596"]},"childChemblIds":["CHEMBL3183086","CHEMBL136478"],"linkedTargets":{"rows":["ENSG00000061918","ENSG00000123201"],"count":2},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0005252","EFO_0000373","EFO_0000319","EFO_0001358","EFO_0001073","EFO_0000537","EFO_1000653","MP_0001914","GO_0007568","MP_0001845","MONDO_0002050","EFO_0008585","EFO_0004517","Orphanet_230","EFO_0003144","EFO_1000645","EFO_0004272","EFO_0000612","EFO_0005251"],"count":20},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 14 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2103795","canonicalSmiles":"CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+]","inchiKey":"IHWFKDWIUSZLCJ-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":true,"name":"AZILSARTAN KAMEDOXOMIL","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL2028661","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Edarbi"],"synonyms":["Azilsartan kamedoxomil","TAK-491"],"crossReferences":{"DailyMed":["azilsartan%20kamedoxomil"],"chEBI":["68847"]},"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["EFO_0000712","EFO_0000537"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for stroke and hypertension. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2104038","canonicalSmiles":"CC(C)OC(=O)OC1CCCCC1","inchiKey":"VTDCYOLLYVAJSY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CILEXETIL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cilexetil"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2106441","canonicalSmiles":"CNC(=S)NCO","inchiKey":"JLMHZVYLAQPMOZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NOXYTIOLIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Noxyflex","Noxyflex 100","Noxyflex-s","Noxyflex-s 100"],"synonyms":["Noxythiolin","Noxytiolin"],"crossReferences":{"drugbank":["DB13838"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL2107574","canonicalSmiles":"COC1CC(=C(c2cccs2)c2cccs2)C[N+](C)(C)C1.[Br-]","inchiKey":"QTSXMEPZSHLZFF-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"TIMEPIDIUM BROMIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1865135","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Timepidium bromide"],"crossReferences":{"PubChem":["144206212","170465823"],"chEBI":["32226"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2108163","drugType":"Unknown","blackBoxWarning":false,"name":"ULINASTATIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AER-002","Bikunin","Estotin","Mingin","Miraclid","Trypsin inhibitor uti-1","Ulinastatin","Urinary trypsin inhibitor 1","Urinastatin","Uristatin"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2108728","drugType":"Enzyme","blackBoxWarning":false,"name":"CALASPARGASE PEGOL","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Asparlas"],"synonyms":["Calaspargase pegol","Calaspargase pegol-mknl","EZN-2285"],"crossReferences":{"DailyMed":["calaspargase%20pegol-mknl"]},"description":"Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for acute lymphoblastic leukemia and lymphoblastic lymphoma and has 1 investigational indication."}
{"id":"CHEMBL2109134","drugType":"Protein","blackBoxWarning":false,"name":"MOLGRAMOSTIM","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Leucomax"],"synonyms":["Granulocyte-macrophage colony-stimulating factor molgramostim","Molgradex","Molgramostim","Molgramostim (genetical recombination)","Molgramostim rdna","SCH 39300","SCH-39300"],"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL2109159","drugType":"Protein","blackBoxWarning":false,"name":"PITRAKINRA","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pitrakinra"],"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109208","drugType":"Unknown","blackBoxWarning":false,"name":"MARITIME PINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cluster pine whole","Maritime pine","Maritime pine whole","Pinus lemoniana whole","Pinus nigrescens whole","Pinus pinaster","Pinus pinaster bark","Pinus pinaster bark extract","Pinus pinaster whole","Pinus syrtica whole","Pycnogenol"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2109342","drugType":"Antibody","blackBoxWarning":false,"name":"HGS-1025","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HGS-1025","Hgs-1025"],"linkedTargets":{"rows":["ENSG00000160791"],"count":1},"linkedDiseases":{"rows":["EFO_0000729"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109523","drugType":"Antibody","blackBoxWarning":false,"name":"M170","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["M170"],"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109547","drugType":"Antibody","blackBoxWarning":false,"name":"ME1-14 F(AB')2","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ME1-14 F(AB')2","Me1-14 f(ab')2"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109563","drugType":"Antibody","blackBoxWarning":false,"name":"RAV-12","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RAV-12","Rav-12"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2110670","canonicalSmiles":"c1cc2c3c(c1)[C@H]1CCC[C@H]1CN3CCNC2","inchiKey":"NPTIPEQJIDTVKR-STQMWFEESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VABICASERIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Vabicaserin"],"crossReferences":{"drugbank":["DB12071"]},"childChemblIds":["CHEMBL2104991","CHEMBL3126691"],"linkedTargets":{"rows":["ENSG00000135914","ENSG00000102468","ENSG00000147246"],"count":3},"linkedDiseases":{"rows":["MONDO_0005090"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2146108","canonicalSmiles":"O=C(CCn1cnc2c(=O)[nH]cnc21)Nc1ccc(C(=O)[O-])cc1.[K+]","inchiKey":"MICLTPPSCUXHJT-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"LETEPRINIM POTASSIUM","maximumClinicalTrialPhase":2,"parentId":"CHEMBL2104345","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Neotrofin"],"synonyms":["AIT-082","Leteprinim potassium","Leteprinim potassium salt"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL218650","canonicalSmiles":"C[C@]1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1","inchiKey":"XDAOLTSRNUSPPH-XMMPIXPASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DELAMANID","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Deltyba"],"synonyms":["Delamanid","OPC-67683","Opc 67683"],"crossReferences":{"Wikipedia":["Delamanid"],"drugbank":["DB11637"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for tuberculosis and has 3 investigational indications."}
{"id":"CHEMBL232202","canonicalSmiles":"OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O","inchiKey":"BJRNKVDFDLYUGJ-RMPHRYRLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARBUTIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Arbutin","Arbutinum","Arbutoside","NSC-4036","Ursin"],"crossReferences":{"PubChem":["144205062","144212745","170465722","93576640"],"Wikipedia":["Arbutin"],"drugbank":["DB11217"],"chEBI":["18305"]},"linkedTargets":{"rows":["ENSG00000077498"],"count":1},"linkedDiseases":{"rows":["EFO_0003963"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL240530","canonicalSmiles":"Cc1ccc(C(=O)N2CCC(Cc3ccccc3)CC2)cc1","inchiKey":"DVOLWKZEIDCCES-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL240530","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07123"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL249837","canonicalSmiles":"C=C1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12","inchiKey":"MHIGBKBJSQVXNH-IWVLMIASSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHACYCLINE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["GS-2876","Metacycline","Methacycline","Motc"],"crossReferences":{"Wikipedia":["Metacycline"],"drugbank":["DB00931"],"chEBI":["6805"]},"childChemblIds":["CHEMBL2146123"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL289277","canonicalSmiles":"Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O","inchiKey":"RHMXXJGYXNZAPX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EMODIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Emodin"],"crossReferences":{"PubChem":["11111157","11111158","124880055","124880057","144210197","144213535","17389019","174006698","26753048","47193718","477762","50105616","50105617","85231039","90340961"],"Wikipedia":["Emodin"],"drugbank":["DB07715"],"chEBI":["42223"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL307189","canonicalSmiles":"CCC(CC)Nc1cc(C(=O)O)ccc1N1C(=O)CCC1(CO)CO","inchiKey":"BNIJJJRESBVRNB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL307189","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03475"],"chEBI":["45265"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3137335","canonicalSmiles":"CC(/C=C/C=C(\\C)C(=O)[O-])=C\\C=C\\C=C(C)\\C=C\\C=C(/C)C(=O)[O-].[Na+].[Na+]","inchiKey":"RMDMBHQVNHQDDD-VFWKRBOSSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"TRANSCROCETINATE SODIUM","maximumClinicalTrialPhase":3,"parentId":"CHEMBL464792","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Disodium trans-crocetinate","TSC","Trans sodium crocetinate","Transcrocetinate sodium"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3183440","canonicalSmiles":"CC=CC(=O)N(CC)c1ccccc1C","inchiKey":"DNTGGZPQPQTDQF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3183440","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144203997","144211121","170464851","174006207"],"drugbank":["DB00265"],"chEBI":["31439"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL322241","canonicalSmiles":"CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1)C(=O)NC(C)(C)C","inchiKey":"ZILOOGIOHVCEKS-HZFUHODCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TELINAVIR","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-670881","SC-52151","Telinavir"],"crossReferences":{"drugbank":["DB12178"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL324794","canonicalSmiles":"OC/C=C/c1ccccc1","inchiKey":"OOCCDEMITAIZTP-QPJJXVBHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CINNAMIC ALCOHOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(E)-Cinnam Alcohol","Cinnamic Alcohol","Cinnamyl Alcohol"],"crossReferences":{"Wikipedia":["Cinnamyl_alcohol"],"drugbank":["DB14186"],"chEBI":["33227"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL324951","canonicalSmiles":"COc1ccc(OC)c(Cc2nc3nc(F)nc(N)c3[nH]2)c1","inchiKey":"MWHAHELTVGJGFJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL324951","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03093"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3319236","canonicalSmiles":"COc1ccc(S(=O)(=O)N[C@@H](CNc2nc(C)nc(N3CCC(c4ccc5c(n4)NCCC5)CC3)c2C)C(=O)O)cc1","inchiKey":"CXHCNOMGODVIKB-VWLOTQADSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GLPG-0187","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GLPG0187","Glpg-0187","Glpg0187"],"crossReferences":{"drugbank":["DB12297"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3414621","canonicalSmiles":"CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1","inchiKey":"NSQSAUGJQHDYNO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TAZEMETOSTAT","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["E-7438","E7438","EPZ-6438","Tazemetostat"],"crossReferences":{"DailyMed":["tazemetostat%20hydrobromide"],"drugbank":["DB12887"]},"childChemblIds":["CHEMBL4594260"],"linkedTargets":{"rows":["ENSG00000106462"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000403","EFO_0005952","MONDO_0001187","EFO_0000588","EFO_0000096","MONDO_0017387","EFO_0000196","EFO_0000574","EFO_0008528","MONDO_0018906","EFO_0000691","EFO_0000181","MONDO_0056819"],"count":14},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for follicular lymphoma and sarcoma and has 10 investigational indications."}
{"id":"CHEMBL3545029","canonicalSmiles":"CN1CC2CCN(c3ccc(-c4ccc(-n5ncccc5=O)cc4)cc3)C2C1","inchiKey":"GNIRITULTPTAQW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ABT-288","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Abt-288"],"linkedTargets":{"rows":["ENSG00000101180"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0004975"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3545057","canonicalSmiles":"CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O","inchiKey":"HPMZBILYSWLILX-UMDUKNJSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACETYLDIGITOXIN","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Acylanid"],"synonyms":["Acetyldigitoxin","Acetyldigitoxins .alpha.-form"],"crossReferences":{"drugbank":["DB00511"],"chEBI":["53773"]},"linkedTargets":{"rows":["ENSG00000163399","ENSG00000018625","ENSG00000105409","ENSG00000132681"],"count":4},"linkedDiseases":{"rows":["EFO_0000319"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease."}
{"id":"CHEMBL3545068","canonicalSmiles":"COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21.Cl.Cl","inchiKey":"STGQPVQAAFJJFX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"COPANLISIB HYDROCHLORIDE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3218576","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aliqopa"],"synonyms":["BAY 80-6946 DIHYDROCHLORIDE","BAY 84-1236","BAY-80-6946 DIHYDROCHLORIDE","BAY-84-1236","Copanlisib dihydrochloride","Copanlisib hydrochloride","Copanlisib hydrochloride hydrate"],"crossReferences":{"DailyMed":["copanlisib%20dihydrochloride"]},"linkedTargets":{"rows":["ENSG00000171608","ENSG00000121879"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000304","MONDO_0019465","EFO_0000096","EFO_0000403","EFO_1001051","MONDO_0018906","EFO_0000183","EFO_1001469","EFO_0000305"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for neoplasm of mature b-cells and follicular lymphoma and has 4 investigational indications."}
{"id":"CHEMBL3545089","drugType":"Small molecule","blackBoxWarning":false,"name":"IMD-0354","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Imd-0354"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545138","drugType":"Small molecule","blackBoxWarning":false,"name":"PRT-2607","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIIB-057","P505-15","PRT-062607","Prt-2607"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545367","canonicalSmiles":"Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1","inchiKey":"MUGXRYIUWFITCP-PGRDOPGGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEMBOREXANT","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dayvigo"],"synonyms":["E-2006","E2006","Lemborexant"],"crossReferences":{"DailyMed":["lemborexant"],"drugbank":["DB11951"]},"linkedTargets":{"rows":["ENSG00000137252","ENSG00000121764"],"count":2},"linkedDiseases":{"rows":["EFO_0003086","EFO_0001421","MONDO_0024361","EFO_0003918","EFO_0004698","EFO_0009878"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for insomnia and has 4 investigational indications."}
{"id":"CHEMBL357021","canonicalSmiles":"Cc1cccc2sc3nncn3c12","inchiKey":"DQJCHOQLCLEDLL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRICYCLAZOLE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144212736","26757226"],"drugbank":["DB02891"],"chEBI":["81783"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3678076","canonicalSmiles":"CCCCOc1cccc(CCNCC(=O)N(C)C)c1","inchiKey":"GRHBODILPPXVKN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EVENAMIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Evenamide","Nw-3509"],"childChemblIds":["CHEMBL4286909"],"linkedTargets":{"rows":["ENSG00000185313","ENSG00000196876","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000153253"],"count":10},"linkedDiseases":{"rows":["MONDO_0005090"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3707286","canonicalSmiles":"COc1ccc(-c2cc(=O)c3c(OCCO)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3o2)cc1O","inchiKey":"XYFLWVOTXWXNAM-WTNNCJBMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HIDROSMIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5-o-(.beta.-hydroxyethyl)diosmin","Hidrosmin"],"crossReferences":{"drugbank":["DB13490"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3707320","canonicalSmiles":"CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl","inchiKey":"GYABBVHSRIHYJR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALECTINIB HYDROCHLORIDE","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1738797","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alecensa"],"synonyms":["Alectinib hydrochloride"],"crossReferences":{"DailyMed":["alectinib%20hydrochloride"]},"linkedTargets":{"rows":["ENSG00000165731","ENSG00000171094","ENSG00000143924"],"count":3},"linkedDiseases":{"rows":["EFO_0003060"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for non-small cell lung carcinoma."}
{"id":"CHEMBL3833350","canonicalSmiles":"O.O=S(=O)([O-])[O-].O=S(=O)([O-])[O-].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-]","inchiKey":"SPPNVMTVMQOKSC-UHFFFAOYSA-A","drugType":"Small molecule","blackBoxWarning":false,"name":"MAGALDRATE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL3833408","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dynese","Riopan"],"synonyms":["AY-5710","Magaldrate","Magnesium aluminate hydrate","Monalium hydrate"],"crossReferences":{"DrugCentral":["4926"],"drugbank":["DB08938"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL3833372","drugType":"Antibody","blackBoxWarning":false,"name":"BRAZIKUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG-139","Brazikumab","MEDI-2070","MEDI2070"],"linkedTargets":{"rows":["ENSG00000110944"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0000384"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3907479","canonicalSmiles":"Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1","inchiKey":"BEMNJULZEQTDJY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FGFR INHIBITOR DEBIO 1347","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fgfr inhibitor debio 1347"],"crossReferences":{"drugbank":["DB12903"]},"linkedTargets":{"rows":["ENSG00000066468","ENSG00000068078","ENSG00000077782"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0007254"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3989562","canonicalSmiles":"COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O","inchiKey":"NZMOFYDMGFQZLS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TERAZOSIN HYDROCHLORIDE","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL611","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Benph","Hytrin","Hytrin bph","Terazosin hydrochloride"],"synonyms":["ABBOTT-45975","ABBOTT-45975 ANHYDROUS","Heitrin","Hytracin","Itrin","NSC-759168","Terazosin (as hydrochloride)","Terazosin hcl","Terazosin hcl 2h20","Terazosin hydrochloride","Terazosin hydrochloride anhydrous","Terazosin hydrochloride dihydrate","Terazosin hydrochloride hydrate","Urodie"],"crossReferences":{"DailyMed":["terazosin%20hydrochloride"]},"linkedTargets":{"rows":["ENSG00000171873","ENSG00000170214","ENSG00000120907"],"count":3},"linkedDiseases":{"rows":["HP_0000726","EFO_0000284"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for benign prostatic hyperplasia and has 1 investigational indication."}
{"id":"CHEMBL3989570","canonicalSmiles":"CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@H](CO)c1ccccc1)C2.CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@H](CO)c1ccccc1)C2.O.O.O=S(=O)(O)O","inchiKey":"BXSVDJUWKSRQMD-ITMJLNKNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYOSCYAMINE SULFATE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL1331216","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Anaspaz","Levsin","Levsin sl","Levsinex","Levsinex timecaps","Neoquess","Peptard"],"synonyms":["Egacene","Egazil duretter","Hyoscyamine sulfate","Hyoscyamine sulfate dihydrate","Hyoscyamine sulphate"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for urinary tract infection."}
{"id":"CHEMBL403741","canonicalSmiles":"Nc1ccc(N)cc1","inchiKey":"CBCKQZAAMUWICA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-Phenylenediamine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-Phenylenediamine","P-Phenylenediamine"],"crossReferences":{"PubChem":["144205168","144209191","144213260","170466858","29215299","29215300"],"drugbank":["DB14141"],"chEBI":["51403"]},"childChemblIds":["CHEMBL3561416"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL406572","canonicalSmiles":"Cc1ccc(-c2cccc(C(=O)N3CCCC(C)(C)C3)n2)cc1F","inchiKey":"SIDDLTBLAQYZIZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL406572","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06992"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4228124","canonicalSmiles":"COc1ccc2c(c1)CC[C@H](CN(C)CC(=O)O)[C@@H]2c1ccccc1","inchiKey":"UEBBYLJZCHTLEG-UTKZUKDTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ORG-25935","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ORG 25935","Org 25935","Org-25935","Org-25935 free base","SCH 900435","SCH-900435","Sch 900435"],"crossReferences":{"drugbank":["DB12220"]},"linkedTargets":{"rows":["ENSG00000196517"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0004262","MONDO_0007079"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297189","name":"CHEMBL4297189","tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB14917"]}}
{"id":"CHEMBL4297544","canonicalSmiles":"C=C(C#N)C(=O)OC(C)CCCCCC","inchiKey":"CQVWXNBVRLKXPE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2-OCTYL CYANOACRYLATE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-octyl cyanoacrylate","Dermabond"],"crossReferences":{"drugbank":["DB12040"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297584","canonicalSmiles":"CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1","inchiKey":"HDXDQPRPFRKGKZ-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TENALISIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tenalisib"],"crossReferences":{"drugbank":["DB15295"]},"linkedTargets":{"rows":["ENSG00000171608","ENSG00000105851"],"count":2},"linkedDiseases":{"rows":["EFO_0000211","MONDO_0009348","EFO_0000095","EFO_0001642","MONDO_0007254","EFO_0000574","EFO_0005952"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4297611","canonicalSmiles":"CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(-c2ccc(F)cc2)n1","inchiKey":"YFHRCLAKZBDRHN-MRXNPFEDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VENGLUSTAT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GENZ-682452","GZ-402671","GZ/SAR402671","GZ402671","Genz-682452","Genz-682452-AA","Gz402671","Ibiglustat","SAR-402671","SAR402671","Venglustat"],"crossReferences":{"drugbank":["DB14966"]},"childChemblIds":["CHEMBL4594270"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL4297638","canonicalSmiles":"Cn1cc(-c2ccc(S(=O)(=O)[C@@H]3C[C@@H](C(=O)NC4(C#N)CC4)N(C(=O)C4(C(F)(F)F)CC4)C3)c(C(F)(F)F)c2)cn1","inchiKey":"KXAAIORSMACJSI-AEFFLSMTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PETESICATIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Petesicatib","RG-7625","RG7625","RO-5459072","RO5459072","Rg7625","Ro5459072"],"crossReferences":{"drugbank":["DB15297"]},"linkedTargets":{"rows":["ENSG00000163131"],"count":1},"linkedDiseases":{"rows":["EFO_0001060","EFO_0000699"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297886","drugType":"Protein","blackBoxWarning":false,"name":"ASUNERCEPT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["APG-101","APG101","Apg101","Apocept","Asinercept","Asunercept","CAN-008"],"linkedTargets":{"rows":["ENSG00000117560"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","MONDO_0100096","EFO_0000519"],"count":3},"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297909","drugType":"Unknown","blackBoxWarning":false,"name":"BFKB-8488A","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BFKB-8488A","BFKB8488A","Bfkb-8488a","Bfkb8488a","RG-7992","RG7992"],"linkedTargets":{"rows":["ENSG00000113578","ENSG00000134962"],"count":2},"linkedDiseases":{"rows":["EFO_0003095","EFO_0002614"],"count":2},"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297945","drugType":"Unknown","blackBoxWarning":false,"name":"EFMOROCTOCOG ALFA","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Efmoroctocog alfa","Efraloctocog alfa","Elocta","Eloctate"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4298026","drugType":"Unknown","blackBoxWarning":false,"name":"MCMV-3068A","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mcmv-3068a","Mcmv3068a"],"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298098","drugType":"Unknown","blackBoxWarning":false,"name":"SAR-408701","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SAR-408701","SAR408701","Sar 408701","Sar-408701","Sar408701","Tusamitamab ravtansine"],"linkedTargets":{"rows":["ENSG00000261456","ENSG00000167553","ENSG00000127824","ENSG00000188229","ENSG00000198033","ENSG00000258947","ENSG00000152086","ENSG00000105388","ENSG00000196230","ENSG00000104833","ENSG00000137267","ENSG00000167552","ENSG00000101162","ENSG00000137285","ENSG00000123416","ENSG00000176014"],"count":16},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003060"],"count":2},"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4303201","canonicalSmiles":"COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1","inchiKey":"KSMZEXLVHXZPEF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANLOTINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AL 3818","AL-3818","AL3818","Al-3818","Anlotinib","Catequentinib"],"linkedTargets":{"rows":["ENSG00000128052","ENSG00000037280","ENSG00000113721","ENSG00000157404"],"count":4},"linkedDiseases":{"rows":["MONDO_0003060","EFO_0003869","EFO_0000756","EFO_0000681","EFO_1000657","EFO_0000333","EFO_1001951","MONDO_0000548","EFO_0000588","EFO_0000564","MONDO_0002974","MONDO_0008903","EFO_0000182","MONDO_0015277","MONDO_0013730","EFO_0002618","EFO_0005922","MONDO_0002108","MONDO_0008170","EFO_1001512","EFO_0005842","EFO_1001968","EFO_0005221","MONDO_0002912","EFO_0007143","EFO_0005537","EFO_0000574","EFO_0003108","EFO_0001376","EFO_0003820","EFO_1001972","MONDO_0100342","MONDO_0021117","MONDO_0007254","EFO_0001071","EFO_0004252","MONDO_0001056","EFO_1001480","EFO_1000044","EFO_0000707","EFO_0000616","EFO_0006859","EFO_0002916","MONDO_0024503","EFO_0000403","Orphanet_44890","EFO_0003060","EFO_0000621","EFO_0000311","MONDO_0056806","EFO_0008549","EFO_0000174","MONDO_0011962","EFO_0000702","MONDO_0002367","EFO_0000691","EFO_0000519","EFO_0000181"],"count":58},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 44 investigational indications."}
{"id":"CHEMBL433921","canonicalSmiles":"COc1cccc(N2C(CN3CCOCC3)=Cc3cc(S(N)(=O)=O)sc3S2(=O)=O)c1","inchiKey":"XSUAVPPTKHUTDX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AL-6629","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AL-6629"],"crossReferences":{"drugbank":["DB03598"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4439321","canonicalSmiles":"COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1","inchiKey":"ACWKGTGIJRCOOM-HHHXNRCGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ATUVECICLIB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Atuveciclib"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL452289","canonicalSmiles":"NC(=O)c1cccc(-c2ccc([C@H](N)Cc3cc(F)ccc3F)cc2)c1","inchiKey":"JYKFWUXBFJJDTP-HXUWFJFHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL452289","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07181"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL457748","canonicalSmiles":"Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)cc(C)c1Cc1ccc(O)c(C(C)C)c1","inchiKey":"LGGPZDRLTDGYSQ-JADSYQMUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MB07811","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MB07811","Mb-07811","Mb07811","VK2809","Vk-2809"],"crossReferences":{"drugbank":["DB15137"]},"linkedTargets":{"rows":["ENSG00000151090"],"count":1},"linkedDiseases":{"rows":["HP_0003124","MONDO_0021187","EFO_1001249"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL458975","canonicalSmiles":"O=C([C@@H]1CC(F)(F)CN1C(=O)CCN1C(=O)c2ccccc2C1=O)N1CCCC1","inchiKey":"ZSXNPAWXICXNGZ-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL458975","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08739"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594516","drugType":"Antibody","blackBoxWarning":false,"name":"REVDOFILIMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ABBV-368","ABBV368","Abbv-368","PR-1628103","PR1628103","Revdofilimab"],"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4594560","drugType":"Gene","blackBoxWarning":false,"name":"ROCAKINOGENE SIFUPLASMID","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["INO-9012","Ino-9012","Rocakinogene sifuplasmid"],"description":"Gene drug with a maximum clinical trial phase of I (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL4650245","drugType":"Protein","blackBoxWarning":false,"name":"ROZIBAFUSP ALFA","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG 570","AMG-570","MEDI-0700","Rozibafusp alfa"],"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4650391","drugType":"Unknown","blackBoxWarning":false,"name":"DI-LEU16-IL2","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Di-leu16-il2","Di-leu16-il2 immunocytokine"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL471524","canonicalSmiles":"Nc1ncnc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[nH]nc12","inchiKey":"KBHMEHLJSZMEMI-KSYZLYKTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FORMYCIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02281"],"chEBI":["42452"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL492320","canonicalSmiles":"CC(C)(C)c1ccc(C(=O)N/N=C/c2cc(Br)c(O)c(Br)c2O)cc1","inchiKey":"FVJUELRQTOWYRY-ZVBGSRNCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL492320","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07097"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL509027","canonicalSmiles":"O=C(O)c1ccc[nH]1","inchiKey":"WRHZVMBBRYBTKZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL509027","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02543"],"chEBI":["36751"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL51483","canonicalSmiles":"Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O","inchiKey":"QBKSWRVVCFFDOT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GOSSYPOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(-)-Gossypol","BL-193","Gossypol","NSC-56817","NSC-624336","No fertil","Pogosin","Tash 1"],"crossReferences":{"PubChem":["104171302","106063","11112318","11114252","124882242","124882244","124882245","124882246","144203985","170466800","26747182","26747183","26752256","26752257","50104971","8139932","90341416"],"Wikipedia":["Gossypol"],"drugbank":["DB13044"]},"childChemblIds":["CHEMBL1516388"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL52333","canonicalSmiles":"CCCn1c(=O)c2nc(C34CC5CC(CC3C5)C4)[nH]c2n(CCC)c1=O","inchiKey":"PJBFVWGQFLYWCB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ROLOFYLLINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["KW 3902","KW-3902","MK-7418","Rolofylline"],"crossReferences":{"PubChem":["137275983"]},"linkedTargets":{"rows":["ENSG00000163485"],"count":1},"linkedDiseases":{"rows":["EFO_0003144","EFO_0000373"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL531048","canonicalSmiles":"O=C1C(=O)c2ncccc2-c2cccnc21","inchiKey":"VLPADTBFADIFKG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHANQUONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["C-11925","GNF-PF-1759","Phanchinone","Phanquinone","Phanquone"],"crossReferences":{"PubChem":["144205320","29216050"],"Wikipedia":["Phanquinone"],"drugbank":["DB13469"],"chEBI":["59141"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL560377","canonicalSmiles":"c1ccc2nc(COc3ccc(-c4n[nH]cc4-c4ccncc4)cc3)ccc2c1","inchiKey":"VRWJZGHUCOFGPZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL560377","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08386"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL56904","canonicalSmiles":"CN1CCN(Cc2ccc(C(=O)Nc3cccc(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1","inchiKey":"JHMBUEWQJDGKGS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Demethyl-imatinib","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Demethyl-imatinib"],"crossReferences":{"drugbank":["DB04739"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL592054","canonicalSmiles":"Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\\CCC(=O)O)c2ccccc2)cc1","inchiKey":"ULVDFHLHKNJICZ-QCWLDUFUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IMIGLITAZAR","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Imiglitazar","TAK-559","Tak-559"],"crossReferences":{"drugbank":["DB12511"]},"linkedTargets":{"rows":["ENSG00000186951","ENSG00000132170"],"count":2},"linkedDiseases":{"rows":["EFO_0000400"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL820","canonicalSmiles":"CS(=O)(=O)OCCCCOS(C)(=O)=O","inchiKey":"COVZYZSDYWQREU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"BUSULFAN","yearOfFirstApproval":1954,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Busilvex","Busulfan","Busulfex","Myleran"],"synonyms":["Busulfan","Busulfanum","Leucosulfan","Myelosan","Myelosanum","NCI-C01592","NSC-750","Sulphabutin"],"crossReferences":{"DailyMed":["busulfan"],"PubChem":["144204589","144209046","144210637","170465232","17388889","17389813","174007363","26747279","26752840","49648470","67633"],"Wikipedia":["Busulfan"],"drugbank":["DB01008"],"chEBI":["28901"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 4 approved and 84 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL866","canonicalSmiles":"COc1c(C)c2c(c(O)c1C/C=C(\\C)CCC(=O)O)C(=O)OC2","inchiKey":"HPNSFSBZBAHARI-RUDMXATFSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MYCOPHENOLIC ACID","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mycophenolic acid","Myfortic"],"synonyms":["68618","Mycophenolate","Mycophenolate mofetil impurity, mycophenolic acid-","Mycophenolic acid","NSC-129185","RS-61443 [AS MOFETIL]"],"crossReferences":{"DailyMed":["mycophenolic%20acid"],"PubChem":["11112696","11112697","11114111","124882524","124882525","124882528","124882529","124882530","144204161","170465182","26747168","26752207","26752208","420202","47193743","50104875","85148364"],"Wikipedia":["Mycophenolic_acid"],"drugbank":["DB01024"],"chEBI":["168396"]},"childChemblIds":["CHEMBL2106643"],"linkedTargets":{"rows":["ENSG00000106348","ENSG00000178035"],"count":2},"linkedDiseases":{"rows":["EFO_0003086","EFO_1001020","EFO_0000540","EFO_1002048","HP_0000083","EFO_0002690","HP_0001871","EFO_0000544","EFO_0003884","EFO_0000182","EFO_0004255","EFO_0005140","EFO_0000717","MONDO_0013730","EFO_0005761","EFO_0002687","EFO_1000906","EFO_0000222","EFO_0000319","EFO_0004599","EFO_0000384","EFO_0001422","EFO_1000986","EFO_0003765","MONDO_0005147","EFO_0000699","EFO_0001062","EFO_0009878"],"count":28},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for immune system disease and has 18 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL92","canonicalSmiles":"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C","inchiKey":"ZDZOTLJHXYCWBA-VCVYQWHSSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DOCETAXEL","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["RP-56976","Taxotere"],"crossReferences":{"DailyMed":["docetaxel"],"PubChem":["124950708","144206334","144206639","170464919","494081"],"Wikipedia":["Docetaxel"],"drugbank":["DB01248"],"chEBI":["4672"]},"childChemblIds":["CHEMBL3545252"],"linkedTargets":{"rows":["ENSG00000261456","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000258947","ENSG00000101162","ENSG00000137285","ENSG00000196230","ENSG00000176014"],"count":9},"linkedDiseases":{"rows":["EFO_0003891","EFO_0011061","EFO_0000637","EFO_0003859","EFO_0000756","EFO_0000681","EFO_0004228","EFO_1000984","EFO_1001951","EFO_0000178","MONDO_0021310","EFO_0000564","MONDO_0002974","MONDO_0008903","MONDO_0001528","EFO_0008528","MONDO_0002038","MONDO_0056819","EFO_0000198","EFO_0002618","EFO_1001931","EFO_0005922","EFO_0006911","HP_0002039","EFO_1001968","MONDO_0004986","MONDO_0008315","EFO_0001663","MONDO_0002691","Orphanet_398934","MONDO_0018201","EFO_1000527","EFO_0004284","EFO_0000574","EFO_0001378","EFO_0001376","EFO_1000412","EFO_0005577","MONDO_0021117","MONDO_0007254","MONDO_0005271","EFO_0004252","MONDO_0020654","EFO_0003817","MONDO_0001056","MONDO_0002158","EFO_1001974","EFO_0000196","EFO_0000707","EFO_0000616","EFO_0003897","EFO_0005088","EFO_0006859","EFO_1000601","EFO_0002916","Orphanet_44890","MONDO_0007576","EFO_0000304","MONDO_0002120","MONDO_0011962","EFO_0000702","EFO_0000199","MONDO_0002367","MONDO_0024880","EFO_0005232","MONDO_0003060","EFO_0003869","EFO_0001075","EFO_0004281","EFO_0000571","MONDO_0004222","EFO_0000228","MONDO_0003212","EFO_0000565","MONDO_0002358","EFO_0000182","MONDO_0003199","HP_0012378","EFO_0001416","Orphanet_145","EFO_1000595","EFO_0003893","EFO_0000466","MONDO_0008170","EFO_0005842","MONDO_0004669","EFO_0007355","EFO_0009708","MONDO_0044787","EFO_1001100","EFO_0005537","HP_0004326","EFO_0002428","EFO_0000233","EFO_0000432","EFO_0006544","EFO_1000613","MONDO_0021355","EFO_1000172","EFO_0002938","MONDO_0004192","EFO_0003866","EFO_0004230","EFO_0000708","MONDO_0021063","MONDO_0002087","MONDO_0024879","EFO_0000305","EFO_1000357","MONDO_0001187","EFO_0007362","EFO_1001480","EFO_1000044","EFO_1000043","MONDO_0001475","EFO_0003860","EFO_0006352","EFO_0000673","EFO_1001963","EFO_0002617","EFO_0002914","MONDO_0001402","EFO_0000503","EFO_0000313","EFO_0003060","EFO_1001214","EFO_0000311","EFO_0003863","EFO_0005570","EFO_0003865","EFO_0010282","EFO_0006861","MONDO_0003219","MONDO_0001325","EFO_0000691","EFO_0000181"],"count":136},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 approved and 105 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL920","canonicalSmiles":"C[N+](C)(C)CCO","inchiKey":"OEYIOHPDSNJKLS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHOLINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Choline"],"crossReferences":{"PubChem":["11110922","90340588"],"Wikipedia":["Choline"],"drugbank":["DB00122"],"chEBI":["15354"]},"childChemblIds":["CHEMBL4297301"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
